Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single-Center Cohort Study

Nagi Tozawa, Takaya Yamashita, Miho Nara, Yuki Fujioka, Sho Ikeda, Takahiro Kobayashi, Isuzu Kobayashi, Akihiro Kitadate, Yoshihiro Kameoka, Naoto Takahashi · 2023

Read Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single-Center Cohort Study by Nagi Tozawa, Takaya Yamashita, Miho Nara, Yuki Fujioka, Sho Ikeda, Takahiro Kobayashi, Isuzu Kobayashi, Akihiro Kitadate, Yoshihiro Kameoka, Naoto Takahashi (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10784717.txt.

Description

Nagi Tozawa and co-authors reviewed care outcomes in 2023 for a fast-growing blood cancer treated at one Japanese hospital. The cancer, a form of acute lymphoblastic leukemia with a known chromosome change, is treated with targeted drugs plus strong chemotherapy. Records covered twenty-three patients over more than twenty years. Thirteen received the newest drug, ponatinib.

Most patients reached deep remission within three months. Three-year survival was strong overall, and ponatinib patients fared far better than those on older drugs. Fast deep remission predicted longer freedom from molecular relapse. The authors suggest ponatinib improves outlook, though the group was small. A protein marker called CD20 may help guide later choices.

Catalog record

CREATORNagi Tozawa, Takaya Yamashita, Miho Nara, Yuki Fujioka, Sho Ikeda, Takahiro Kobayashi, Isuzu Kobayashi, Akihiro Kitadate, Yoshihiro Kameoka, Naoto Takahashi
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10784717

Browse the full library · About the Tower of Babel